AngioDynamics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 month.
- Its last 4 Sell calls were actually followed by a +11% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -18.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth D-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -1.9% | Better than 18% |
| Net income CAGR (3Y) | -33.9% | Better than 10% |
| Free cash flow CAGR (3Y) | -20.5% | Better than 18% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 54.6% | Better than 69% |
| Operating margin | -7.0% | Better than 16% |
| Net margin | -11.5% | Better than 15% |
| Return on equity | -20.8% | Better than 16% |
| Return on invested capital | -20.8% | Better than 13% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -31.4% | Better than 17% |
| 6-month return | -9.3% | Better than 41% |
| 12-month return (ex latest month) | 0.6% | Better than 34% |
| Distance below 52-week high | 33.6% | Better than 36% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.2x | Better than 60% |
| Debt to assets | 1.5% | Better than 90% |
| Interest coverage | -19.1x | Better than 10% |
| Free cash flow / net income | 230.4% | Better than 81% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 10.76
- Open
- 10.65
- Day range
- 10.53 - 10.99
- Avg price
- 10.79
- Volume
- 430.81K
- Turnover
- 4.65M
- Turnover ratei
- 1.13%
- Volume ratioi
- 1.18
- Amplitudei
- 4.28%
- 52-week rangei
- 9.39 - 16.29
Valuation
- P/Ei
- -12.28
- P/E (TTM)i
- -13.68
- P/Bi
- 2.77
- EPSi
- -0.88
- Book value / shi
- 3.90
- Net profit
- -37.01M
- Net assets
- 163.97M
Share structure
- Market cap
- 454.61M
- Float capi
- 410.98M
- Shares out
- 42.05M
- Float sharesi
- 38.02M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
33.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.37M net over the window
Short interest
- Shares short
- 2.00M
- % of floati
- 4.76%
- Days to coveri
- 2.92
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of AngioDynamics (ANGO)?
AngioDynamics last traded at 10.81. This page shows a periodic quote snapshot. Check the displayed quote time.
What is AngioDynamics's market cap?
About 454.61M.
What is the P/E ratio of AngioDynamics?
The trailing twelve-month P/E is -13.68. The Valuation tab shows it against the stock's own five-year range.
Does AngioDynamics pay a dividend?
AngioDynamics does not currently pay a regular dividend.
Is AngioDynamics a buy according to analysts?
The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 19.00, which implies 75.8% upside from the current price. This is not investment advice.
What is AngioDynamics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates AngioDynamics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:01:15 · For reference only, not investment advice and not tailored to your situation.
AngioDynamics discussion 0 comments